Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML.
AML
NK cell-mediated cytotoxicity
NK cells
combined blockade of TIGIT and CD39 or A2AR
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
29 Nov 2021
29 Nov 2021
Historique:
received:
22
10
2021
revised:
26
11
2021
accepted:
26
11
2021
entrez:
10
12
2021
pubmed:
11
12
2021
medline:
13
1
2022
Statut:
epublish
Résumé
This study aimed to characterize different natural killer (NK) cell phenotypes on bone marrow and peripheral blood cells from acute myeloid leukemia (AML) patients and healthy donors (HDs). Our data show that CD56
Identifiants
pubmed: 34884723
pii: ijms222312919
doi: 10.3390/ijms222312919
pmc: PMC8657570
pii:
doi:
Substances chimiques
ADORA2A protein, human
0
Receptor, Adenosine A2A
0
Receptors, Immunologic
0
TIGIT protein, human
0
Apyrase
EC 3.6.1.5
ENTPD1 protein, human
EC 3.6.1.5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : J. S.z.W. was supported by the DFG
ID : SFB841 project A6
Organisme : E. S. was supported by the E.W. Kuhlmann Stiftung
Organisme : F.B. and S.M. were supported by the MSNZ, University Medical Center Hamburg-Eppendorf
Organisme : F. K.-N. was supported by the DFG
ID : SFB1328 (project Z02)
Références
Front Immunol. 2019 Oct 11;10:2357
pubmed: 31681270
J Transl Med. 2019 May 20;17(1):165
pubmed: 31109341
Clin Cancer Res. 2018 Aug 15;24(16):4006-4017
pubmed: 29666301
Front Immunol. 2019 May 31;10:1187
pubmed: 31214171
J Exp Med. 2016 Feb 8;213(2):167-76
pubmed: 26755705
Immunology. 2009 Apr;126(4):458-65
pubmed: 19278419
Cancer Res. 2018 Feb 15;78(4):1003-1016
pubmed: 29229601
Cancer Immunol Immunother. 2020 Nov;69(11):2371-2380
pubmed: 32524362
FASEB J. 2007 Nov;21(13):3490-8
pubmed: 17575259
Front Oncol. 2020 Aug 07;10:1595
pubmed: 32903786
Oncoimmunology. 2020 Nov 8;9(1):1843247
pubmed: 33224630
Front Immunol. 2018 Aug 13;9:1869
pubmed: 30150991
Proc Natl Acad Sci U S A. 2021 Jun 1;118(22):
pubmed: 34050021
Cancers (Basel). 2019 Jun 23;11(6):
pubmed: 31234588
Cancers (Basel). 2021 Mar 17;13(6):
pubmed: 33802954
Front Cell Infect Microbiol. 2020 Feb 13;10:49
pubmed: 32117816
Cell. 2020 Feb 20;180(4):749-763.e13
pubmed: 32059780
Signal Transduct Target Ther. 2020 Oct 29;5(1):250
pubmed: 33122640
Front Immunol. 2017 Jun 28;8:760
pubmed: 28702032
Front Immunol. 2017 Sep 13;8:1124
pubmed: 28955340
Retrovirology. 2013 Dec 18;10:158
pubmed: 24351015
J Immunol. 2015 Aug 1;195(3):965-72
pubmed: 26091716
Front Immunol. 2015 Jul 27;6:368
pubmed: 26284063
J Immunother Cancer. 2018 Jun 18;6(1):57
pubmed: 29914571
J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):467-472
pubmed: 27930600
Immunol Cell Biol. 2012 Jan;90(1):109-15
pubmed: 21383766
J Clin Invest. 2015 May;125(5):2046-58
pubmed: 25866972
J Hematol Oncol. 2020 Dec 7;13(1):167
pubmed: 33287858
Front Immunol. 2018 Jan 23;8:1989
pubmed: 29410663
Cancer Immunol Immunother. 2021 Jun 15;:
pubmed: 34129052
Nat Rev Immunol. 2016 Mar;16(3):177-92
pubmed: 26922909
Front Immunol. 2017 Mar 16;8:293
pubmed: 28360915
Cold Spring Harb Perspect Biol. 2012 Mar 01;4(3):
pubmed: 22383753
Oncoimmunology. 2018 May 24;7(8):e1466769
pubmed: 30221069
Front Immunol. 2019 Jan 21;9:3095
pubmed: 30719024
Cancer. 2019 May 1;125(9):1470-1481
pubmed: 30500073
Oncogene. 2018 Sep;37(39):5269-5280
pubmed: 29855615
J Hematol Oncol. 2021 Jun 26;14(1):100
pubmed: 34174928
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2886-91
pubmed: 15699323
Front Immunol. 2021 Jun 17;12:683381
pubmed: 34220833
J Clin Invest. 2020 Mar 2;130(3):1185-1198
pubmed: 31770109
Haematologica. 2020 Nov 05;106(12):3115-3124
pubmed: 33147937
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32727810
Cancer Immunol Res. 2020 Mar;8(3):356-367
pubmed: 31992567
Curr Opin Chem Eng. 2018 Mar;19:9-20
pubmed: 29623254
Exp Mol Med. 2017 Mar 31;49(3):e311
pubmed: 28360428
Cancer Immunol Immunother. 2018 Jun;67(6):861-872
pubmed: 29500635
J Immunother Cancer. 2020 Dec;8(2):
pubmed: 33428584
Nat Rev Clin Oncol. 2020 Oct;17(10):611-629
pubmed: 32514148
Front Immunol. 2016 Mar 29;7:109
pubmed: 27066002
Nat Immunol. 2018 Jul;19(7):723-732
pubmed: 29915296
Cancers (Basel). 2020 Dec 30;13(1):
pubmed: 33396591
Blood. 2010 May 27;115(21):4293-301
pubmed: 20233969
Front Immunol. 2019 May 31;10:1205
pubmed: 31214177
Cancers (Basel). 2020 Nov 06;12(11):
pubmed: 33172030
Oncoimmunology. 2019 Apr 2;8(6):e1593809
pubmed: 31069159
Front Immunol. 2017 Jun 19;8:699
pubmed: 28674534
Front Immunol. 2021 Jan 08;11:618427
pubmed: 33488631
J Immunol. 2018 Apr 15;200(8):3000-3007
pubmed: 29500245
Cancers (Basel). 2021 Feb 03;13(4):
pubmed: 33546248
Blood Adv. 2019 Nov 26;3(22):3674-3687
pubmed: 31765481
Int J Med Sci. 2020 Jul 19;17(13):1964-1973
pubmed: 32788875
Blood. 2005 Mar 1;105(5):2066-73
pubmed: 15536144
Hematol Oncol Stem Cell Ther. 2015 Jun;8(2):47-55
pubmed: 25571788
Front Immunol. 2018 Oct 30;9:2533
pubmed: 30425720
Cancers (Basel). 2020 Aug 05;12(8):
pubmed: 32764229
Blood. 1999 Dec 1;94(11):3864-71
pubmed: 10572102
Immunol Rev. 2017 Mar;276(1):121-144
pubmed: 28258700
J Clin Invest. 2020 Jun 1;130(6):3051-3068
pubmed: 32134744
Immunol Cell Biol. 2011 Feb;89(2):216-24
pubmed: 20567250